News
RHHBY
52.65
+0.52%
0.27
Chugai Pharmaceutical publishes 2025 annual report
PUBT · 16h ago
Foundation Medicine integrates Roche navify Clinical Hub to expand digital oncology decision-support tools
PUBT · 1d ago
Wall Street Underestimates Novo Nordisk's GLP-1 Comeback
Seeking Alpha · 1d ago
South Korea: Asia's Second Innovation Engine
Seeking Alpha · 2d ago
Immunic names ex-Genentech executive Erik Lundgren CEO, replacing Daniel Vitt
PUBT · 2d ago
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Benzinga · 2d ago
Deutsche Bank Sticks to Their Hold Rating for Roche Holding AG (RHHVF)
TipRanks · 2d ago
Roche's New Liver Disease Panel Brings Certified Digital Algorithms To Transform Chronic Liver Disease Management Worldwide
Benzinga · 2d ago
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
Seeking Alpha · 3d ago
Verastem Oncology appoints AVEO CEO Michael P. Bailey to board
PUBT · 3d ago
Weekly Report: what happened at RHHBY last week (0518-0522)?
Weekly Report · 4d ago
Foundation Medicine to present 14 genomic profiling abstracts at ASCO annual meeting
PUBT · 05/22 11:05
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
Seeking Alpha · 05/21 21:40
Graphic Packaging files Form 3 for SVP, Chief Commercial Officer Jean-Francois Roche
PUBT · 05/21 20:47
FDA approves FoundationOne CDx as TEPMETKO companion diagnostic in NSCLC
PUBT · 05/21 15:36
3 Vanguard Dividend ETFs to Boost Passive Income in 2026
TipRanks · 05/21 10:50
Trump Trade: Trump announces expansion of TrumpRx.gov
TipRanks · 05/19 13:56
3G Capital Exits Microsoft Stock in Major Portfolio Shift. MSFT Is Still One of the Best AI Plays Now.
Barchart · 05/19 12:02
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
Barchart · 05/19 00:05
BRIEF-MPP and Roche Sign Voluntary Licence Agreement For Baloxavir Marboxil
Reuters · 05/18 16:17
More
Webull provides a variety of real-time RHHBY stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHBY
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.